Long term effect of MD1003 (high dose pharmaceutical grade biotin) in a cohort of patients with progressive non-active multiple sclerosis

被引：0
|
作者：
Donze, C. [1 ]
Guyot, M. A. [1 ]
Kwiatkowski, A. [2 ]
Hautecoeur, P. [2 ]
Massot, C. [1 ]
机构：
[1] Inst Catholique Lille, Grp Hosp, Rehabil, Lille, France
[2] Inst Catholique Lille, Grp Hosp, Neurol, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P756
引用
收藏
页码：385 / 385
页数：1
相关论文
共 50 条
  • [1] Effect of MD1003 (high dose pharmaceutical grade biotin) on dexterity, cognitive, and quality of life measures in a cohort of patients with non-active progressive multiple sclerosis
    Donze, C.
    Guyot, M. A.
    Lenne, B.
    Massot, C.
    Kwiatkowski, A.
    Hautecoeur, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 915 - 915
  • [2] Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003)
    Collongues, Nicolas
    Kuhle, Jens
    Tsagkas, Charidimos
    Lamy, Julien
    Meyer, Nicolas
    Barro, Christian
    Parmar, Katrin
    Amann, Michael
    Wuerfel, Jens
    Kappos, Ludwig
    Moreau, Thibault
    Seze, Jerome
    [J]. BRAIN AND BEHAVIOR, 2021, 11 (02):
  • [3] High dose pharmaceutical grade biotin (MD1003) protects axons in a TMEV-induced mouse model of progressive multiple sclerosis
    Warrington, A.
    Perdomini, M.
    Bernard, D.
    Rodriguez, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 532 - 533
  • [4] Real-world effectiveness of MD1003 (high dose pharmaceutical grade biotin) in patients with progressive MS
    Faure, J.
    Jauffret, J.
    Carreau, C.
    Legrain, P.
    Castex, C.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 281 - 282
  • [5] Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis
    Saint Paul, Laure Peyro
    Debruyne, Daniele
    Bernard, Delphine
    Mock, Donald M.
    Defer, Gilles L.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 327 - 344
  • [6] High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study
    Juntas-Morales, Raul
    Pageot, Nicolas
    Bendarraz, Abdelkarim
    Alphandery, Sebastien
    Sedel, Frederic
    Seigle, Stephanie
    Camu, William
    [J]. ECLINICALMEDICINE, 2020, 19
  • [7] Effect of MD1003 (High-Dose Pharmaceutical Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): Subgroup Analyses
    Laplaud, David-Axel
    Gout, Olivier
    Clavelou, Pierre
    Pelletier, Jean
    Simon, Olivier
    Sedel, Frederic
    Tourbah, Ayman
    Lasser, Robert
    Morteau, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 33 - 33
  • [8] Annual Relapse Rates (ARR) in Patients with Spinal Progressive Multiple Sclerosis Treated with MD1003 (High-Dose Pharmaceutical Biotin)
    Morteau, Olivier
    Lasser, Robert
    Sedel, Frederic
    Brion, Guillaume
    Tourbah, Ayman
    Simon, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 31 - 31
  • [9] High dose pharmaceutical grade biotin, MD1003, treatment preserves motor performance in a model of progressive neurodegeneration
    Nessler, S.
    Winkler, A.
    van der Meer, F.
    Gargareta, S.
    Cobos, A.
    Stadelmann, C.
    Nave, K. A.
    Brueck, W.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 311 - 311
  • [10] Treatment of progressive MS with MD1003 (high dose pharmaceutical grade biotin): real-world evidence
    Ciron, J.
    Pignolet, B.
    Bucciarelli, F.
    Biotti, D.
    Lerebours, F.
    Dorcet, G.
    Rabadeux, C.
    Freitas, N.
    Bonneville, F.
    Brassat, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 693 - 693
12345